MCID: DFF037
MIFTS: 44

Diffuse Intrinsic Pontine Glioma

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Diffuse Intrinsic Pontine Glioma

MalaCards integrated aliases for Diffuse Intrinsic Pontine Glioma:

Name: Diffuse Intrinsic Pontine Glioma 49 55 69
Dipg 49 55
Infiltrative Brainstem Glioma 49

Classifications:



External Ids:

Orphanet 55 ORPHA497188
UMLS 69 C2986658

Summaries for Diffuse Intrinsic Pontine Glioma

NIH Rare Diseases : 49 This condition doesn't have a summary yet. Please see our page(s) on Childhood brain stem glioma.

MalaCards based summary : Diffuse Intrinsic Pontine Glioma, also known as dipg, is related to glioma and glioma susceptibility 1. An important gene associated with Diffuse Intrinsic Pontine Glioma is H3F3A (H3 Histone Family Member 3A), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Vincristine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include brain, pons and spinal cord, and related phenotype is G0/1 arrest.

Wikipedia : 72 A diffuse intrinsic pontine glioma (DIPG) is a tumour located in the pons (middle) of the brain stem.... more...

Related Diseases for Diffuse Intrinsic Pontine Glioma

Graphical network of the top 20 diseases related to Diffuse Intrinsic Pontine Glioma:



Diseases related to Diffuse Intrinsic Pontine Glioma

Symptoms & Phenotypes for Diffuse Intrinsic Pontine Glioma

GenomeRNAi Phenotypes related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 G0/1 arrest GR00098-A-2 9.1 HIST1H3B HIST1H3D HIST1H3E HIST1H3G PARP1 PLK1

Drugs & Therapeutics for Diffuse Intrinsic Pontine Glioma

Drugs for Diffuse Intrinsic Pontine Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 3,Phase 1,Phase 2 2068-78-2, 57-22-7 5978
2
Etoposide Approved Phase 3,Phase 1 33419-42-0 36462
3
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
4
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
5
Ifosfamide Approved Phase 3 3778-73-2 3690
6
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
7
Lomustine Approved, Investigational Phase 3,Phase 2 13010-47-4 3950
8
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
9
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
10
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
11
Valproic Acid Approved, Investigational Phase 3,Phase 2 99-66-1 3121
12
Dacarbazine Approved, Investigational Phase 3,Phase 1,Phase 2,Early Phase 1 4342-03-4 5351166
13
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
14
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
16 Isophosphamide mustard Phase 3 0
17 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
18 glucocorticoids Phase 3
19 Folic Acid Antagonists Phase 3
20 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
21 Nucleic Acid Synthesis Inhibitors Phase 3
22 Hormone Antagonists Phase 3
23 Dermatologic Agents Phase 3
24 Vitamin B Complex Phase 3
25 Hormones Phase 3
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
27 Etoposide phosphate Phase 3,Phase 1
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antimetabolites Phase 3,Phase 1,Early Phase 1
30 Anti-Inflammatory Agents Phase 3
31 Antimetabolites, Antineoplastic Phase 3,Phase 1,Early Phase 1
32 Antimitotic Agents Phase 3,Phase 1,Phase 2
33 Antineoplastic Agents, Hormonal Phase 3
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2,Early Phase 1
35 Antirheumatic Agents Phase 3,Phase 1,Phase 2
36 Calcium, Dietary Phase 3
37 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
38 Central Nervous System Depressants Phase 3,Phase 2
39 GABA Agents Phase 3,Phase 2
40 Neurotransmitter Agents Phase 3,Phase 2
41 Tranquilizing Agents Phase 3,Phase 2
42 Anthelmintics Phase 3,Phase 1,Phase 2
43 Anticonvulsants Phase 3,Phase 2,Phase 1
44 Antimanic Agents Phase 3,Phase 2
45 Psychotropic Drugs Phase 3,Phase 2,Phase 1
46 Antiparasitic Agents Phase 3,Phase 1,Phase 2
47 Chloroquine diphosphate Phase 3 50-63-5
48 Analgesics Phase 3
49 Analgesics, Non-Narcotic Phase 3
50 Peripheral Nervous System Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 59)

# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
2 Prospective Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children Unknown status NCT01878266 Phase 3
3 International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013) Not yet recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid;Temozolomide + Chloroquine
4 Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children Completed NCT01777633 Phase 1, Phase 2
5 Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma Completed NCT00600054 Phase 2
6 Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma Completed NCT00028795 Phase 2 temozolomide
7 A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas Completed NCT00036569 Phase 2
8 Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Completed NCT01836549 Phase 2 imetelstat sodium
9 Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors Completed NCT01751308 Phase 1, Phase 2 Cabazitaxel (XRP6258)
10 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication Recruiting NCT02233049 Phase 2 Erlotinib;Everolimus;Dasatinib
11 Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma Recruiting NCT02758366 Phase 2 Doxorubicin
12 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
13 Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 Recruiting NCT01884740 Phase 1, Phase 2 SIACI of Erbitux and Bevacizumab
14 Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas Recruiting NCT02343406 Phase 2 ABT-414;Lomustine;Temozolomide
15 Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) Active, not recruiting NCT01182350 Phase 2 Bevacizumab;Erlotinib;Temozolomide
16 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Active, not recruiting NCT01189266 Phase 1, Phase 2 Vorinostat
17 Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma Active, not recruiting NCT01952769 Phase 1, Phase 2
18 A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas Active, not recruiting NCT02750891 Phase 1, Phase 2 DSP-7888
19 Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT) Active, not recruiting NCT01469247 Phase 1, Phase 2
20 Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma Active, not recruiting NCT00879437 Phase 2 Valproic acid;Bevacizumab
21 A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy Active, not recruiting NCT02607124 Phase 1, Phase 2 Ribociclib
22 A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG) Active, not recruiting NCT02742883 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
23 Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents Terminated NCT01517776 Phase 2 Cilengitide;Temozolomide
24 Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma Completed NCT01400672 Phase 1 Imiquimod
25 PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma Completed NCT01393912 Phase 1 Crenolanib
26 Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) Completed NCT00996723 Phase 1 vandetanib and dasatinib
27 Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma Completed NCT01165333 Phase 1 Cilengitide dose escalation;Cilengitide
28 ZD6474 to Treat Advanced Brain Cancer in Patients Completed NCT00272350 Phase 1 Steroids;ZD6474
29 Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG) Recruiting NCT02420613 Phase 1 Vorinostat;Temsirolimus
30 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma Recruiting NCT02717455 Phase 1 LBH589
31 CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With DIPG Recruiting NCT03086616 Phase 1 Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)
32 WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Recruiting NCT01922076 Phase 1 Adavosertib
33 ONC201 in Pediatric H3 K27M Gliomas Recruiting NCT03416530 Phase 1 ONC201
34 Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas Recruiting NCT03178032 Phase 1
35 H3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas Recruiting NCT02960230 Phase 1
36 Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Recruiting NCT02644460 Phase 1 Abemaciclib
37 Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, or Hypermutated Brain Tumors Recruiting NCT02359565 Phase 1
38 Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) Recruiting NCT01644773 Phase 1 Crizotinib;Dasatinib
39 Phase I Study of APX005M in Pediatric CNS Tumors Recruiting NCT03389802 Phase 1
40 A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG Recruiting NCT03330197 Phase 1 oral veledimex
41 Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy Recruiting NCT01502917 Phase 1
42 Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Recruiting NCT02644291 Phase 1 Mebendazole
43 A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Recruiting NCT03355794 Phase 1 ribociclib;Everolimus
44 Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors Recruiting NCT02502708 Phase 1 Indoximod;Temozolomide;Cyclophosphamide;Etoposide
45 Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas Active, not recruiting NCT01222754 Phase 1 Lenalidomide
46 Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines Active, not recruiting NCT02840123 Phase 1
47 Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) Not yet recruiting NCT03396575 Phase 1 Cyclophosphamide + Fludarabine Lymphodepletive Conditioning;Dose-Intensified TMZ;Td vaccine
48 Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors Not yet recruiting NCT03387020 Phase 1 Everolimus;Ribociclib
49 Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). Suspended NCT01688401 Phase 1 Melphalan hydrochloride
50 Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors Suspended NCT02444546 Phase 1

Search NIH Clinical Center for Diffuse Intrinsic Pontine Glioma

Genetic Tests for Diffuse Intrinsic Pontine Glioma

Anatomical Context for Diffuse Intrinsic Pontine Glioma

MalaCards organs/tissues related to Diffuse Intrinsic Pontine Glioma:

38
Brain, Pons, Spinal Cord, Eye, Endothelial

Publications for Diffuse Intrinsic Pontine Glioma

Articles related to Diffuse Intrinsic Pontine Glioma:

(show top 50) (show all 72)
# Title Authors Year
1
REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. ( 29435175 )
2018
2
Characterization of Diffuse Intrinsic Pontine Glioma Radiosensitivity using Synchrotron Microbeam Radiotherapy and Conventional Radiation Therapy In Vitro. ( 29364085 )
2018
3
T2-weighted images are superior to other MR image types for the determination of diffuse intrinsic pontine glioma intratumoral heterogeneity. ( 29151166 )
2018
4
End-of-life care of children with diffuse intrinsic pontine glioma. ( 29397521 )
2018
5
Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma. ( 29143272 )
2018
6
Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. ( 29207163 )
2018
7
Correction to: A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. ( 29063425 )
2018
8
A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. ( 28748343 )
2017
9
Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation. ( 28428205 )
2017
10
Preliminary dosimetric study on feasibility of multi-beam boron neutron capture therapy in patients with diffuse intrinsic pontine glioma without craniotomy. ( 28662135 )
2017
11
Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma. ( 28542253 )
2017
12
Lessons learned from diffuse intrinsic pontine glioma: how a terrible disease forced us to think better. ( 28541486 )
2017
13
Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma. ( 29118968 )
2017
14
Multiregional tumor drug-uptake imaging by PET and microvascular morphology in end-stage diffuse intrinsic pontine glioma. ( 28818988 )
2017
15
Genomic Insights into Diffuse Intrinsic Pontine Glioma. ( 28401062 )
2017
16
Neonatal Respiratory Failure Caused by Congenital Diffuse Intrinsic Pontine Glioma. ( 28116951 )
2017
17
Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. ( 28434841 )
2017
18
Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. ( 28821206 )
2017
19
Positron emission tomography imaging in diffuse intrinsic pontine glioma. ( 28856152 )
2017
20
External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry. ( 28560664 )
2017
21
Targeting CDK7 or BRD4 Blocks Diffuse Intrinsic Pontine Glioma Growth. ( 28455397 )
2017
22
BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. ( 28968963 )
2017
23
Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients. ( 29088386 )
2017
24
MRI and PET: Noninvasive Tools to Probe the Biology of Diffuse Intrinsic Pontine Glioma. ( 28385794 )
2017
25
Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models. ( 28052119 )
2017
26
Rapid and fulminant leptomeningeal spread following radiotherapy in diffuse intrinsic pontine glioma. ( 28084680 )
2017
27
Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy. ( 29165288 )
2017
28
Characterization of Diffuse Intrinsic Pontine Glioma Radiosensitivity using Synchrotron Microbeam Radiotherapy and Conventional Radiation Therapy In Vitro. ( 29189105 )
2017
29
The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. ( 28450157 )
2017
30
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG). ( 28362421 )
2017
31
Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies. ( 28947132 )
2017
32
Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma. ( 28592748 )
2017
33
Palliative Care Options for a Young Adult Patient with a Diffuse Intrinsic Pontine Glioma. ( 29057192 )
2017
34
Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma. ( 28947983 )
2017
35
Untangling the role of mutant histone H3 in diffuse intrinsic pontine glioma. ( 28388610 )
2017
36
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. ( 28966033 )
2017
37
Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates. ( 29164054 )
2017
38
Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma. ( 28790919 )
2017
39
Biopsy for diffuse intrinsic pontine glioma: a reappraisal. ( 27153377 )
2016
40
Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey. ( 26459800 )
2016
41
Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report. ( 27329600 )
2016
42
Conventional and Advanced Imaging of Diffuse Intrinsic Pontine Glioma. ( 27071471 )
2016
43
Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models. ( 27325687 )
2016
44
Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. ( 26487690 )
2016
45
MRI Evaluation of Non-Necrotic T2-Hyperintense Foci in Pediatric Diffuse Intrinsic Pontine Glioma. ( 27197987 )
2016
46
The Optimal Dose of Hypofractionated Radiotherapy in Diffuse Intrinsic Pontine Glioma. ( 26999071 )
2016
47
Molecular Drug Imaging: 89Zr-bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma. ( 27765855 )
2016
48
Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma. ( 26903150 )
2016
49
Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets. ( 27157264 )
2016
50
Reply: The Optimal Dose of Hypofractionated Radiotherapy in Diffuse Intrinsic Pontine Glioma (DIPG). ( 26840880 )
2016

Variations for Diffuse Intrinsic Pontine Glioma

Expression for Diffuse Intrinsic Pontine Glioma

Search GEO for disease gene expression data for Diffuse Intrinsic Pontine Glioma.

Pathways for Diffuse Intrinsic Pontine Glioma

Pathways related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.19 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
2
Show member pathways
14 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
3
Show member pathways
13.9 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
4
Show member pathways
13.89 ACVR1 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C
5
Show member pathways
13.86 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
6
Show member pathways
13.84 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
7
Show member pathways
13.83 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
8
Show member pathways
13.62 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
9
Show member pathways
13.6 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
10
Show member pathways
13.58 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
11
Show member pathways
13.51 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
12
Show member pathways
13.42 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
13
Show member pathways
13.41 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
14
Show member pathways
13.26 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
15
Show member pathways
13.15 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
16
Show member pathways
13.13 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
17
Show member pathways
13.11 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
18
Show member pathways
13.02 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
19
Show member pathways
12.84 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
20
Show member pathways
12.5 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
21
Show member pathways
12.49 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
22
Show member pathways
12.37 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
23 12.3 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
24
Show member pathways
12.09 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
25 12 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
26 10.77 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F

GO Terms for Diffuse Intrinsic Pontine Glioma

Cellular components related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 nuclear chromosome GO:0000228 9.93 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
2 nucleosome GO:0000786 9.73 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
3 nuclear nucleosome GO:0000788 9.4 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
4 nucleus GO:0005634 10.38 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
5 membrane GO:0016020 10.34 ACVR1 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E
6 extracellular exosome GO:0070062 10.28 DDAH1 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C
7 nucleoplasm GO:0005654 10.28 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
8 extracellular region GO:0005576 10.27 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
9 chromosome GO:0005694 10.18 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
10 protein complex GO:0043234 10.13 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
11 nuclear chromosome, telomeric region GO:0000784 10.07 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D

Biological processes related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 chromatin organization GO:0006325 9.96 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
2 protein heterotetramerization GO:0051290 9.85 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
3 DNA replication-dependent nucleosome assembly GO:0006335 9.65 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
4 DNA replication-independent nucleosome assembly GO:0006336 9.57 H3F3A H3F3B
5 positive regulation of protein localization to nucleus GO:1900182 9.56 PARP1 PLK1
6 regulation of gene silencing GO:0060968 9.32 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
7 regulation of gene silencing by miRNA GO:0060964 10.33 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
8 blood coagulation GO:0007596 10.31 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
9 chromatin silencing at rDNA GO:0000183 10.3 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
10 nucleosome assembly GO:0006334 10.29 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
11 positive regulation of gene expression, epigenetic GO:0045815 10.27 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
12 cellular protein metabolic process GO:0044267 10.26 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
13 regulation of hematopoietic stem cell differentiation GO:1902036 10.23 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
14 regulation of megakaryocyte differentiation GO:0045652 10.21 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
15 negative regulation of gene expression, epigenetic GO:0045814 10.18 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
16 telomere organization GO:0032200 10.15 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
17 interleukin-7-mediated signaling pathway GO:0038111 10.02 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F

Molecular functions related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cadherin binding GO:0045296 9.96 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
2 protein heterodimerization activity GO:0046982 9.93 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
3 histone binding GO:0042393 9.73 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
4 nucleosomal DNA binding GO:0031492 9.4 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
5 protein binding GO:0005515 10.3 ACVR1 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C
6 DNA binding GO:0003677 10.13 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D

Sources for Diffuse Intrinsic Pontine Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....